

**WW ADNI Minutes**  
**September 8, 2008**  
**3:00 pm CST**

**Attendees:** Maria Carrillo, Anthony Ganst, Bradford Navia, Mike Weiner, Colin Masters, Alison Drone, John Trojanowski

**US ADNI – Status of Add-On Studies**  
**Genotyping and Analysis**  
**Update from Mike Weiner on Genotyping Analysis**

TGEN completed the genotyping testing on 676/821 ADNI subjects. Data is available on the website. Art Toga is getting the data and working on making it public. Everybody thinks by December all of the information will be up on the LONI website. Once the remaining subjects are tested that information will go up. Happening slower than expected but is going well. The bulk of the data should be up on the website within the next few weeks. They will be getting some press releases out on it and they will notify the Alzheimer's Association of that so the press releases can go to the Alzheimer's Association.

**CSF Extension**  
**CFS Extension Project**

The project was funded for one year but unfortunately for a wide range reasons in terms of enrollment, it is going slowly. Only 30 subjects total have consented for additional CSF. It may be a total of 35. The numbers are disappointing but they will analyze whatever they get. Remember for year 2 and 3, this is a subset of the total 411 and they wanted to get 50 AD, 50 MCI, 50 normal control in year 2 and the same people in year 3. Every site has been called to encourage them, but for unforeseen reasons it is not happening. It is difficult to make protocol changes in the middle of a trial which is at various sites with hundreds of patients especially for something like this, lumbar puncture.

Participation of 160 patients (20%) of 800 was expected but the group received a response of 411 CFS. This is the baseline. They are proceeding at a trajectory which makes us think they may get 90% of the 411. They were realistic about the challenges of the year 2 and year 3 extensions. The 33 is a breakdown of 12 normal, 17 MCI and 4 AD; 410 LP at baseline, 315 at 112, and 33 at 124, they're expecting 19 more for year 2 and no more for year 1. Year 1 is closed with a number of 315. They could have as many as 47 more year 2 LP; year 2 subjects are still coming in. Currently collected 33 for year 2 with a possibility of 47 more. Issue has been that the subject will come in but the site is not ready but this should not be a problem in year 3.

Overall, things are going well with the grant that have additional funds for the next few years to carry them over. Working with industry to work out a budget for renewal. Some companies have said they are going to support ADNI for renewal; verbal assurances from Pfizer, Allon, Neely and Merck that they are going to support a renewal application. Unfortunately, GSK has informed us they are not going to participate in the renewal because of major budget cutbacks. \$500,000 per year impact without the participation of GSK.

Question for John Trojanowski: the plasma kit, how far have you got with those? We are planning to do this in January; they have to do a round robin just like they did for the CFS. All of the baseline CFS data is up on the ADNI website, so is the data on the 7 site round robin. They are going to try to do fewer sites for plasma but this is important. The kits might be ready in the next month or two but they will not be able to get to the round robin until January 2009.

### **October 21 Maximizing ADNI II Meeting**

FDA and Alzheimer's Association is co-hosting this meeting. An agenda is being developed. ADNI core leaders have been invited and the ISAB members have been invited. Additionally, anyone from WW\_ADNI is invited and one or two leaders from one of the major programs can come. There will be a question and answer discussion with Russell Katz who runs the therapeutic branch of FDA and this discussion is on 10/21. On 10/23 the FDA sponsored Amyloid meeting will take place. It is an open forum inviting people during a certain time of the day to present information to the FDA on Amyloid and Amyloid imaging. This is a full day meeting which starts at 8 am and goes to 5 pm.

Avid, GE and Bayer – major companies working with amyloid imaging. The Association has had conversations with Avid and GE regarding Amyloid imaging. David Lee is having conversations with Bayer regarding joining ADNI.

### **Introduction of Chinese-ADNI**

Jianping Jia was suppose to join us with an update on a ADNI project unfortunately he was unable to join us. Mike sent a PPT file which describes the 11-5 year project. It is an extremely ambition project concerning Alzheimer's disease with two aspects of it: one is community based and the other is more center based, Alzheimer's memory clinic based. It is a very large number of patients who are going to be seen and followed clinically and cognitively. There is some imaging, no lumbar puncture that he can remember, and no pet scanning. Very ambitious and he is a very impressive gentleman. He told them he would like to encourage him to use ADNI methods and to join the WW\_ADNI group and data sharing. He has not heard from Jia but he was involved with the Olympics and he is probably taking a vacation after that. The study is based in Beijing. Jia is chairman of China Neurologist Association, president of the Chinese Neurologic Association, director of department of Neurology at Xong Wu Hospital in Beijing at Beijing Capital University. We would love to have him join WW\_ADNI and hear more about his project. Capital Medical School is one of the best in China; it is the former Rockefeller of Beijing University.

### **E-ADNI/NEUGRID**

#### **Final Report of Pilot and Expansion Update**

Giovanni sent out a link to everyone to download some slides he will review for the meeting. The paper describing the results of the European ADNI pilot has come out recently. A second paper is presently submitted. The specific feature of the pilot European ADNI is they collected samples of CSF and plasma, both fresh and frozen. The paper which is presently submitted aims to evaluate the agreement between the fresh and frozen sample. A paper is under preparation for the more advanced imaging features. European and American colleagues have recently launched an effort to develop SOP for Hippocampus volumetrics. The aim of the project is to harmonize the available protocol for the manual for ultimate tracing of the hippocampus.

### **J-ADNI**

Good Morning, It is 5 am, very early morning of September 9<sup>th</sup>.

Today, Dr. Arai is talking in place of Dr. Iwatsubo, because Dr. Iwatsubo is absent for conference. I am a Clinical and Biomarker PI of J-ADNI. First of all, I am very glad to report that J-ADNI finally started since we have a first patient successfully enrolled at National center hospital of Neurology and Psychiatry, Tokyo. And I heard that start-up meetings have been done in another 3-4 sites.

The other thing I want to mention today is that I will convene annual meeting of Japan Dementia Society in Sendai, November 21-22, 2009. I am planning a joint meeting of WW-ADNI and Japan Dementia Society

hopefully inviting some of the PIs from US-ADNI, E- and A-ADNI. I have heard that Alzheimer's Association is interested in supporting.

## **A-ADNI**

### **Update on AIBL and ADNI data uploading**

The imaging is waiting for the follow ups to come in. In terms of making the data available through the ADNI website, they are progressing. They are working with a test site and they have starting uploading data and resolving issues as they arise. They do think they will have any major problems and expect to have most of the data available by the end of the year. They finished negotiations with Pfizer to do the plasma biomarker with IBM. That should happen within the next month or two. They will also do their own genome wide study using a different source.

### **New Business – Future Agenda Items**

There is a meeting on April 27, 2009 in Seattle, Washington, USA. The ISAB meeting will be in the afternoon of the 26<sup>th</sup> along with any other key meetings on the 26<sup>th</sup>.

### **Upcoming Call Dates**

**January 12, 2009 next teleconference at 2:30pm CST.**